| Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors (NCT07589530) | Beijing Biotech | 2026-03-02 |
| Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors (NCT07523529) | Beijing Biotech | 2026-03-02 |
| Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma (NCT07622940) | Beijing Biotech | 2026-03-02 |
| Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer (NCT07641036) | Beijing Biotech | 2026-03-02 |
| Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer (NCT07589543) | Beijing Biotech | 2026-03-02 |
| Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma (NCT07551336) | Beijing Biotech | 2026-03-02 |
| Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer (NCT07551362) | Beijing Biotech | 2026-03-02 |
| Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer (NCT07641049) | Beijing Biotech | 2026-03-02 |
| Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma (NCT07510815) | Beijing Biotech | 2026-03-02 |
| Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies (NCT07523555) | Beijing Biotech | 2026-03-02 |
| SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus (NCT07523542) | Beijing Biotech | 2026-03-02 |
| Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma (NCT07598955) | Beijing Biotech | 2026-03-02 |
| Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma (NCT07492628) | Beijing Biotech | 2026-03-02 |
| Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma (NCT07627711) | Beijing Biotech | 2026-03-02 |
| Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 (NCT07617753) | Beijing Biotech | 2026-03-02 |
| Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC (NCT07641023) | Beijing Biotech | 2026-03-02 |
| Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma (NCT07627698) | Beijing Biotech | 2026-03-02 |
| Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma (NCT07502287) | Beijing Biotech | 2026-03-02 |
| Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) (NCT07744256) | Beijing Biotech | 2026-03-02 |
| EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC (NCT07617805) | Beijing Biotech | 2026-03-02 |
| PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors (NCT07510828) | Beijing Biotech | 2026-03-02 |
| Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC (NCT07500220) | Beijing Biotech | 2026-03-02 |
| Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) (NCT07480954) | Beijing Biotech | 2026-02-04 |
| Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) (NCT07480213) | Beijing Biotech | 2026-02-02 |
| Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer (NCT07589517) | Beijing Biotech | 2026-02-02 |
| Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma (NCT07480941) | Beijing Biotech | 2026-02-02 |
| Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma (NCT07551349) | Beijing Biotech | 2026-02-02 |
| Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC (NCT07467863) | Beijing Biotech | 2026-02-02 |
| Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC (NCT07510802) | Beijing Biotech | 2026-02-02 |
| Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) (NCT07486089) | Beijing Biotech | 2026-02-02 |
| Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma (NCT07480928) | Beijing Biotech | 2026-02-02 |
| Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer (NCT07462650) | Beijing Biotech | 2026-02-01 |